CD133 expression: a potential prognostic marker for non-small cell lung cancers
CD133 expression: a potential prognostic marker for non-small cell lung cancers
复制标题
DOI：
10.1007/s10147-013-0541-x
复制
发表时间：
2014-04-01
影响因子：
3.3
通讯作者：
Nishimura, Masaharu
中科院分区：
文献类型：
--
作者：
Mizugaki, Hidenori;Sakakibara-Konishi, Jun;Nishimura, Masaharu
CD133是一种膜糖蛋白，含有五个跨膜环。先前的报告表明，具有广泛增殖和自我更新特征的CD133阳性多能细胞亚群具有癌症干细胞的生物学特征。此外，与 CD133 阴性细胞相比，CD133 阳性细胞的存在与某些实体瘤的预后显着较差相关。然而，CD133在非小细胞肺癌（NSCLC）中的临床病理意义仍存在争议。我们对1982年至1994年间在北海道大学医院手术切除的161例NSCLC进行了免疫组织化学评估，以评估CD133表达与各种临床病理特征之间的相关性。CD133表达与病理分期（pStages）显着相关 分析的各种 NSCLC 类型的 II、III 和 IV 期是该人群不良预后的独立因素（风险比 = 3.157，P = 0.015）。CD133 表达与 pStage 相关，可预测 pStage II、III 和 IV NSCLC 患者的不良预后。这些结果表明可以使用 CD133 作为这些患者的新型预后标志物。
CD133 is a membrane glycoprotein containing five transmembrane loops. Previous reports suggest that a CD133-positive subpopulation of multipotent cells with extensive proliferative and self-renewal characteristics has biological features of a cancer stem cell. In addition, the presence of CD133-positive cells was associated with a significantly poorer prognosis for some solid tumors, compared to those with CD133-negative cells. However, the clinicopathological significance of CD133 in non-small cell lung cancer (NSCLC) remains controversial.We conducted immunohistochemical assessment of 161 NSCLCs surgically resected at Hokkaido University Hospital between 1982 and 1994 to evaluate correlations between CD133 expression and various clinicopathological features.CD133 expression was significantly correlated with pathological stages (pStages) II, III, and IV for the various NSCLC types analyzed and was an independent factor for unfavorable prognosis in this population (hazard ratio = 3.157, P = 0.015).CD133 expression was correlated with pStage and was predictive of unfavorable prognosis in patients with pStages II, III, and IV NSCLC. These results suggest the possibility of using CD133 as a novel prognostic marker in these patients.